Editas Medicine Company Profile (NASDAQ:EDIT)

About Editas Medicine (NASDAQ:EDIT)

Editas Medicine logoEditas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:EDIT
  • CUSIP: N/A
  • Web: www.editasmedicine.com
Capitalization:
  • Market Cap: $674.39 million
  • Outstanding Shares: 40,729,000
Average Prices:
  • 50 Day Moving Avg: $16.68
  • 200 Day Moving Avg: $19.08
  • 52 Week Range: $12.43 - $29.20
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.59
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $5.93 million
  • Price / Sales: 109.07
  • Book Value: $5.07 per share
  • Price / Book: 3.13
Profitability:
  • EBIDTA: ($108,330,000.00)
  • Net Margins: -1,864.00%
  • Return on Equity: -63.29%
  • Return on Assets: -39.62%
Debt:
  • Debt-to-Equity Ratio: 0.16%
  • Current Ratio: 7.04%
  • Quick Ratio: 7.04%
Misc:
  • Average Volume: 705,897 shs.
  • Beta: 5.41
  • Short Ratio: 7.59
 
Frequently Asked Questions for Editas Medicine (NASDAQ:EDIT)

What is Editas Medicine's stock symbol?

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

How were Editas Medicine's earnings last quarter?

Editas Medicine, Inc. (NASDAQ:EDIT) posted its quarterly earnings results on Monday, May, 15th. The company reported ($0.85) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.62) by $0.23. The company had revenue of $0.68 million for the quarter, compared to the consensus estimate of $1 million. Editas Medicine had a negative net margin of 1,864.00% and a negative return on equity of 63.29%. The business's revenue was down 16.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.80) EPS. View Editas Medicine's Earnings History.

Where is Editas Medicine's stock going? Where will Editas Medicine's stock price be in 2017?

7 analysts have issued twelve-month target prices for Editas Medicine's shares. Their predictions range from $17.00 to $35.00. On average, they anticipate Editas Medicine's stock price to reach $28.00 in the next year. View Analyst Ratings for Editas Medicine.

What are analysts saying about Editas Medicine stock?

Here are some recent quotes from research analysts about Editas Medicine stock:

  • 1. According to Zacks Investment Research, "Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts. " (7/18/2017)
  • 2. Cann analysts commented, "We are initiating coverage of Editas Medicine, a development-stage biotechnology platform company, with a Perform rating. Editas is developing gene editing therapies for the treatment of various human diseases. Its gene editing system, CRISPR, utilizes short sequences of RNA to guide a DNA cutting enzyme (DNA nuclease) to cut specific sequences of DNA. We anticipate Editas Medicine will continue to form collaborations for its CRISPR technology and advance its current collaborations into later stages of development." (7/17/2017)
  • 3. Chardan Capital analysts commented, "We initiate coverage of Editas Medicine (EDIT) with a Buy rating (PT $65), on our view of the company's IP breadth and strength providing significant upside potential for shares, via both internal and partnered program opportunities. Editas is a preclinical biotech company aiming to treat various genetic conditions through the CRISPR gene editing system, in which a CRISPR guide RNA (gRNA) delivers a nuclease (a sort of "DNA scissors") to specifically modify a particular DNA sequence to treat diseases. Editas' lead asset, targeting Leber's congenital amaurosis type 10 (LCA10), could be one of the first CRISPR therapies to enter the clinic. An IND filing is expected by year-end 2017." (3/27/2017)
  • 4. Cowen and Company analysts commented, "Today Editas partnered its ophthalmology CRISPR programs with Allergan for $90MM." (3/15/2017)
  • 5. Jefferies Group LLC analysts commented, "We gained incremental color on IP and pipeline progress from our meeting. Mgmt continues to be confident about their broad IP portfolio, which allows them to be prepared for any possible outcome from ongoing interference proceedings. The LCA10 IND filing remains on track by YE17 and likely would require a RAC meeting. Mgmt laid out key elements for the IND filing package and expect to present NHP data at medical meetings in 2017." (2/15/2017)

Who are some of Editas Medicine's key competitors?

Who are Editas Medicine's key executives?

Editas Medicine's management team includes the folowing people:

  • Katrine S. Bosley, President, Chief Executive Officer, Director
  • Andrew A. F. Hack, Chief Financial Officer
  • Charles Albright, Chief Scientific Officer
  • Gerald Cox, Chief Medical Officer
  • Andrew Hirsch, Director
  • Akshay K. Vaishnaw M.D., Ph.D., Director
  • Kevin J. Bitterman Ph.D., Independent Director
  • Alexis Borisy, Independent Director
  • Douglas G. Cole M.D., Independent Director

When did Editas Medicine IPO?

(EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Who owns Editas Medicine stock?

Editas Medicine's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Nisa Investment Advisors LLC (0.19%), Fox Run Management L.L.C. (0.08%), First American Bank (0.04%), Hershey Trust Co. (0.04%) and Creative Planning (0.02%). Company insiders that own Editas Medicine stock include Alexandra Glucksmann, Andrew A F Hack, Boris Nikolic, Gerald Frank Cox, James E Flynn, Kevin Bitterman, Kevin P Starr and Polaris Venture Management Co. View Institutional Ownership Trends for Editas Medicine.

Who bought Editas Medicine stock? Who is buying Editas Medicine stock?

Editas Medicine's stock was bought by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, Fox Run Management L.L.C., First American Bank, Hershey Trust Co. and Creative Planning. Company insiders that have bought Editas Medicine stock in the last two years include Boris Nikolic, Gerald Frank Cox and James E Flynn. View Insider Buying and Selling for Editas Medicine.

How do I buy Editas Medicine stock?

Shares of Editas Medicine can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Editas Medicine's stock price today?

One share of Editas Medicine stock can currently be purchased for approximately $15.88.


MarketBeat Community Rating for Editas Medicine (NASDAQ EDIT)
Community Ranking:  1.9 out of 5 ()
Outperform Votes:  56 (Vote Outperform)
Underperform Votes:  91 (Vote Underperform)
Total Votes:  147
MarketBeat's community ratings are surveys of what our community members think about Editas Medicine and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Editas Medicine (NASDAQ:EDIT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $28.00 (76.32% upside)

Analysts' Ratings History for Editas Medicine (NASDAQ:EDIT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/18/2017Oppenheimer Holdings, Inc.Market PerformN/AView Rating Details
7/17/2017CannInitiated CoverageMarket PerformHighView Rating Details
7/13/2017SunTrust Banks, Inc.Initiated CoverageHold -> Hold$17.00HighView Rating Details
3/27/2017Chardan CapitalInitiated CoverageBuy -> BuyHighView Rating Details
3/15/2017Cowen and CompanyReiterated RatingBuyLowView Rating Details
3/8/2017J P Morgan Chase & CoSet Price TargetHold$32.00LowView Rating Details
2/15/2017Jefferies Group LLCReiterated RatingBuy$35.00N/AView Rating Details
2/29/2016Morgan StanleyInitiated CoverageEqual -> Equal Weight$28.00N/AView Rating Details
2/29/2016JMP SecuritiesInitiated CoverageOutperform$40.00N/AView Rating Details
(Data available from 7/27/2015 forward)

Earnings

Earnings History for Editas Medicine (NASDAQ:EDIT)
Earnings by Quarter for Editas Medicine (NASDAQ:EDIT)
Earnings History by Quarter for Editas Medicine (NASDAQ EDIT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2017Q1 2017($0.62)($0.85)$1.00 million$0.68 millionViewN/AView Earnings Details
3/7/2017Q4 2016($0.62)($1.10)$1.11 million$0.90 millionViewListenView Earnings Details
11/7/2016Q3($0.64)($0.59)$1.00 million$1.00 millionViewListenView Earnings Details
8/9/2016Q2($0.54)($0.54)$3.52 million$3.39 millionViewListenView Earnings Details
5/16/2016Q116($0.23)($0.80)$1.08 million$0.80 millionViewListenView Earnings Details
3/30/2016Q4($0.52)($4.05)$0.79 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Editas Medicine (NASDAQ:EDIT)
2017 EPS Consensus Estimate: ($2.86)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.66)($0.66)($0.66)
Q2 20171($0.70)($0.70)($0.70)
Q3 20171($0.73)($0.73)($0.73)
Q4 20171($0.77)($0.77)($0.77)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Editas Medicine (NASDAQ:EDIT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Editas Medicine (NASDAQ:EDIT)
Institutional Ownership Percentage: 67.76%
Insider Trades by Quarter for Editas Medicine (NASDAQ:EDIT)
Institutional Ownership by Quarter for Editas Medicine (NASDAQ:EDIT)
Insider Trades by Quarter for Editas Medicine (NASDAQ:EDIT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/2/2017Boris NikolicDirectorBuy35,000$14.07$492,450.00View SEC Filing  
6/2/2017Gerald Frank CoxInsiderBuy4,000$14.15$56,600.00View SEC Filing  
5/22/2017Kevin BittermanDirectorSell1,000,000$17.00$17,000,000.00View SEC Filing  
3/15/2017Alexandra GlucksmannCOOSell1,000$26.41$26,410.00View SEC Filing  
2/15/2017Alexandra GlucksmannCOOSell6,000$20.58$123,480.00View SEC Filing  
2/15/2017Andrew A F HackCFOSell3,000$19.20$57,600.00View SEC Filing  
1/11/2017Andrew A F HackCFOSell15,000$19.20$288,000.00View SEC Filing  
12/7/2016Polaris Venture Management Co.Major ShareholderSell75,000$15.82$1,186,500.00View SEC Filing  
12/6/2016Kevin BittermanDirectorSell130,000$15.79$2,052,700.00View SEC Filing  
11/23/2016Kevin BittermanDirectorSell21,480$15.71$337,450.80View SEC Filing  
11/22/2016Polaris Venture Management Co.Major ShareholderSell12,819$15.77$202,155.63View SEC Filing  
11/15/2016Kevin BittermanDirectorSell88,900$16.96$1,507,744.00View SEC Filing  
9/8/2016Polaris Venture Management Co.Major ShareholderSell500,000$16.80$8,400,000.00View SEC Filing  
9/6/2016Kevin P. StarrMajor ShareholderSell5,890$15.90$93,651.00View SEC Filing  
8/23/2016Alexandra GlucksmannCOOSell1,000$20.00$20,000.00View SEC Filing  
2/8/2016James E FlynnInsiderBuy100,000$16.00$1,600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Editas Medicine (NASDAQ:EDIT)
Latest Headlines for Editas Medicine (NASDAQ:EDIT)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to Editas Medicine, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 5:56 PM
americanbankingnews.com logoOppenheimer Holdings Comments on Editas Medicine, Inc.'s FY2017 Earnings (EDIT)
www.americanbankingnews.com - July 20 at 10:35 AM
americanbankingnews.com logoEditas Medicine, Inc. (EDIT) Downgraded by Zacks Investment Research
www.americanbankingnews.com - July 18 at 10:20 PM
americanbankingnews.com logoCann Initiates Coverage on Editas Medicine, Inc. (NASDAQ:EDIT)
www.americanbankingnews.com - July 17 at 7:15 PM
americanbankingnews.com logoSunTrust Banks, Inc. Initiates Coverage on Editas Medicine, Inc. (EDIT)
www.americanbankingnews.com - July 16 at 5:14 PM
benzinga.com logoBenzinga's Top Upgrades, Downgrades For July 14, 2017 - Benzinga
www.benzinga.com - July 14 at 3:09 PM
finance.yahoo.com logoETFs with exposure to Editas Medicine, Inc. : July 14, 2017
finance.yahoo.com - July 14 at 3:09 PM
americanbankingnews.com logoEditas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - July 12 at 10:11 PM
americanbankingnews.com logoEditas Medicine, Inc. (NASDAQ:EDIT) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - July 12 at 8:26 PM
fool.com logoHere's Why Editas Medicine Inc. Bounced Up 20% in June -- The ... - Motley Fool
www.fool.com - July 12 at 12:18 AM
finance.yahoo.com logoEditas Medicine, Inc. breached its 50 day moving average in a Bearish Manner : EDIT-US : July 11, 2017
finance.yahoo.com - July 11 at 7:18 PM
finance.yahoo.com logoHere's Why Editas Medicine Inc. Bounced Up 20% in June
finance.yahoo.com - July 11 at 7:18 PM
finance.yahoo.com logoEditas Medicine, Inc. – Value Analysis (NASDAQ:EDIT) : July 3, 2017
finance.yahoo.com - July 3 at 6:01 PM
finance.yahoo.com logoEditas Medicine, Inc. breached its 50 day moving average in a Bearish Manner : EDIT-US : June 30, 2017
finance.yahoo.com - June 30 at 6:27 PM
finance.yahoo.com logoEditas Medicine to Participate in Investor Conferences in June
finance.yahoo.com - June 13 at 12:08 PM
americanbankingnews.com logoEditas Medicine, Inc. (EDIT) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - June 13 at 11:14 AM
bizjournals.com logoCRISPR pioneer Feng Zhang's lab spawns a new Cambridge biotech
www.bizjournals.com - June 11 at 10:03 PM
americanbankingnews.com logoInsider Buying: Editas Medicine Inc (EDIT) Insider Acquires 4,000 Shares of Stock
www.americanbankingnews.com - June 6 at 8:40 PM
americanbankingnews.com logoBoris Nikolic Buys 35,000 Shares of Editas Medicine Inc (EDIT) Stock
www.americanbankingnews.com - June 6 at 7:51 PM
globenewswire.com logoEditas Medicine Names Andrew Hirsch to Board of Directors - GlobeNewswire (press release)
globenewswire.com - May 31 at 8:55 PM
finance.yahoo.com logoEditas Medicine Names Andrew Hirsch to Board of Directors
finance.yahoo.com - May 31 at 8:55 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Valeant Pharmaceuticals and Editas Medicine
finance.yahoo.com - May 31 at 9:45 AM
finance.yahoo.com logoStudy raises concerns over gene-editing, hitting Cambridge biotechs hard
finance.yahoo.com - May 30 at 4:46 PM
americanbankingnews.com logoEditas Medicine Inc (EDIT) Short Interest Update
www.americanbankingnews.com - May 28 at 8:14 AM
seekingalpha.com logoEditas: The Long Haul Ahead
seekingalpha.com - May 27 at 3:33 AM
americanbankingnews.com logoEditas Medicine Inc (EDIT) Director Sells $17,000,000.00 in Stock
www.americanbankingnews.com - May 24 at 7:20 PM
prnewswire.com logoResearch Reports Coverage on Biotech Stocks -- Editas Medicine, Global Blood Therapeutics, Geron, and Infinity ... - PR Newswire (press release)
www.prnewswire.com - May 24 at 4:40 PM
americanbankingnews.com logoEditas Medicine Inc (EDIT) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 19 at 2:02 PM
nasdaq.com logoEditas Medicine Announces First Quarter 2017 Results and Update ... - Nasdaq
www.nasdaq.com - May 16 at 4:51 PM
rttnews.com logoEditas Medicine Inc. (EDIT) Is Falling After Q1 Loss Widens
www.rttnews.com - May 16 at 11:57 AM
finance.yahoo.com logoEditas reports 1Q loss
finance.yahoo.com - May 16 at 11:57 AM
finance.yahoo.com logoEdited Transcript of EDIT earnings conference call or presentation 15-May-17 9:00pm GMT
finance.yahoo.com - May 16 at 11:57 AM
americanbankingnews.com logoEditas Medicine Inc (EDIT) Posts Earnings Results, Misses Estimates By $0.14 EPS
www.americanbankingnews.com - May 15 at 9:20 PM
reuters.com logoBRIEF-Editas Medicine Q1 loss per share $0.85
www.reuters.com - May 15 at 4:40 PM
finance.yahoo.com logoInvestor Network: Editas Medicine, Inc. to Host Earnings Call
finance.yahoo.com - May 15 at 4:40 PM
finance.yahoo.com logoEditas Medicine Announces First Quarter 2017 Results and Update
finance.yahoo.com - May 15 at 4:40 PM
nasdaq.com logoWhy Editas Medicine (EDIT) Might Surprise This Earnings Season - Nasdaq
www.nasdaq.com - May 14 at 9:18 AM
globenewswire.com logoEditas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate Retinas - GlobeNewswire (press release)
www.globenewswire.com - May 14 at 9:18 AM
finance.yahoo.com logoEditas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate Retinas
finance.yahoo.com - May 13 at 4:48 PM
bizjournals.com logoHow Alphabet's venture arm is fueling the Mass. life science cluster
www.bizjournals.com - May 12 at 5:21 PM
finance.yahoo.com logoWhy Editas Medicine (EDIT) Might Surprise This Earnings Season
finance.yahoo.com - May 12 at 5:21 PM
nasdaq.com logoEditas Medicine Announces Pre-Clinical Data for Program to Treat Sickle Cell Disease and Beta-Thalassemia - Nasdaq
www.nasdaq.com - May 11 at 10:32 PM
finance.yahoo.com logoEditas Medicine Announces Pre-Clinical Data for Program to Treat Sickle Cell Disease and Beta-Thalassemia
finance.yahoo.com - May 11 at 5:31 PM
globenewswire.com logoEditas Medicine to Present at Investor Conferences in May - GlobeNewswire (press release)
globenewswire.com - May 9 at 7:32 AM
finance.yahoo.com logoEditas Medicine to Host Conference Call Discussing First Quarter 2017 Corporate Update and Results
finance.yahoo.com - May 8 at 4:46 PM
finance.yahoo.com logoEditas Medicine to Present at Investor Conferences in May
finance.yahoo.com - May 8 at 4:46 PM
nasdaq.com logoCan Ligand (LGND) Spring a Surprise this Earnings Season?
www.nasdaq.com - May 4 at 11:43 AM
finance.yahoo.com logoCEOs of top gene-editing firms got huge compensation hikes last year
finance.yahoo.com - April 27 at 5:26 PM
finance.yahoo.com logoToday's Bell Ringer, April 25, 2017
finance.yahoo.com - April 25 at 11:39 AM
streetinsider.com logoEditas Medicine (EDIT) to Present New Data Showing Advancements for Translating CRISPR Technologies into Medicines at ASGCT
www.streetinsider.com - April 24 at 4:45 PM

Social

Chart

Editas Medicine (EDIT) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff